Travere Therapeutics, Inc. (NASDAQ:TVTX) Shares Acquired by Healthcare of Ontario Pension Plan Trust Fund

Healthcare of Ontario Pension Plan Trust Fund lifted its holdings in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) by 37.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 843,300 shares of the company’s stock after buying an additional 228,300 shares during the quarter. Healthcare of Ontario Pension Plan Trust Fund owned approximately 1.08% of Travere Therapeutics worth $11,798,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in TVTX. Assenagon Asset Management S.A. raised its stake in shares of Travere Therapeutics by 912.5% during the 2nd quarter. Assenagon Asset Management S.A. now owns 2,214,099 shares of the company’s stock worth $18,200,000 after buying an additional 1,995,419 shares during the period. Vanguard Group Inc. raised its stake in shares of Travere Therapeutics by 13.6% during the 1st quarter. Vanguard Group Inc. now owns 6,265,829 shares of the company’s stock worth $48,310,000 after buying an additional 750,686 shares during the period. Millennium Management LLC raised its stake in shares of Travere Therapeutics by 33.9% during the 2nd quarter. Millennium Management LLC now owns 2,949,335 shares of the company’s stock worth $24,244,000 after buying an additional 747,406 shares during the period. Emerald Advisers LLC increased its position in shares of Travere Therapeutics by 19.8% during the third quarter. Emerald Advisers LLC now owns 1,960,659 shares of the company’s stock worth $27,430,000 after purchasing an additional 323,513 shares in the last quarter. Finally, Emerald Mutual Fund Advisers Trust increased its position in shares of Travere Therapeutics by 26.0% during the third quarter. Emerald Mutual Fund Advisers Trust now owns 1,185,709 shares of the company’s stock worth $16,588,000 after purchasing an additional 244,444 shares in the last quarter.

Travere Therapeutics Trading Down 1.9 %

Shares of Travere Therapeutics stock opened at $18.70 on Friday. Travere Therapeutics, Inc. has a 52 week low of $5.12 and a 52 week high of $20.33. The business’s fifty day simple moving average is $17.03 and its 200-day simple moving average is $11.66. The company has a quick ratio of 1.68, a current ratio of 1.71 and a debt-to-equity ratio of 24.96.

Travere Therapeutics (NASDAQ:TVTX) last announced its quarterly earnings results on Thursday, October 31st. The company reported ($0.70) EPS for the quarter, beating the consensus estimate of ($0.71) by $0.01. Travere Therapeutics had a negative return on equity of 537.74% and a negative net margin of 172.75%. The business had revenue of $62.90 million for the quarter, compared to analyst estimates of $60.87 million. During the same quarter in the prior year, the company posted ($1.17) EPS. The company’s quarterly revenue was up 69.6% on a year-over-year basis. Research analysts predict that Travere Therapeutics, Inc. will post -3.94 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts recently commented on the company. Bank of America boosted their price target on Travere Therapeutics from $18.00 to $20.00 and gave the stock a “buy” rating in a research report on Wednesday, October 9th. Wells Fargo & Company upgraded Travere Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their price target for the stock from $9.00 to $27.00 in a research report on Monday, October 21st. JPMorgan Chase & Co. upped their target price on Travere Therapeutics from $20.00 to $23.00 and gave the company an “overweight” rating in a report on Friday, September 13th. Wedbush upped their target price on Travere Therapeutics from $17.00 to $25.00 and gave the company an “outperform” rating in a report on Wednesday, October 9th. Finally, Scotiabank upped their target price on Travere Therapeutics from $23.00 to $27.00 and gave the company a “sector outperform” rating in a report on Friday, November 1st. Two investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $22.62.

Insider Buying and Selling

In related news, CAO Sandra Calvin sold 12,090 shares of the stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $18.30, for a total transaction of $221,247.00. Following the transaction, the chief accounting officer now owns 54,927 shares of the company’s stock, valued at approximately $1,005,164.10. This represents a 18.04 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Eric M. Dube sold 21,125 shares of the stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $11.52, for a total value of $243,360.00. Following the transaction, the chief executive officer now directly owns 361,975 shares in the company, valued at approximately $4,169,952. The trade was a 5.51 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 122,797 shares of company stock valued at $1,725,559. Corporate insiders own 3.75% of the company’s stock.

Travere Therapeutics Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.